Agilus Diagnostics Partners with Lucence to Bring Advanced Cancer Liquid Biopsy Testing to India
核心洞察
Agilus Diagnostics (搜索) and Lucence (搜索) have formed a strategic partnership to integrate advanced molecular testing technologies for cancer (搜索) detection and monitoring in India.
The collaboration introduces LiquidHALLMARK (搜索), a next-generation sequencing liquid biopsy test that analyzes both ctDNA and ctRNA, capable of identifying mutations in 80 genes and 37 RNA fusions.
This partnership aims to address India's significant cancer (搜索) burden, where 1.46 million new cancer cases and 916,000 cancer-related deaths occur annually.
In a significant move to advance cancer (搜索) diagnostics in India, Agilus Diagnostics (搜索) has partnered with molecular diagnostics firm Lucence (搜索) to integrate cutting-edge molecular testing technologies into the country's cancer care landscape. The collaboration marks a crucial step forward in bringing precision oncology solutions to a nation grappling with a substantial cancer burden.
The centerpiece of this partnership is the integration of LiquidHALLMARK (搜索), a sophisticated next-generation sequencing liquid biopsy platform, into Agilus' oncology diagnostics portfolio. This advanced testing solution analyzes both circulating tumor DNA (搜索) (ctDNA) and circulating tumor RNA (搜索) (ctRNA), offering comprehensive molecular insights for cancer (搜索) detection and treatment selection.
Technical Capabilities and Clinical Impact
LiquidHALLMARK (搜索)'s capabilities extend to identifying somatic mutations across 80 ctDNA genes and 37 ctRNA fusions, providing oncologists with detailed molecular profiles to guide treatment decisions. This comprehensive genetic analysis enables more precise and personalized treatment approaches for cancer (搜索) patients.
Dr. Anand K, Managing Director & CEO of Agilus Diagnostics (搜索), emphasized the significance of the collaboration: "Our collaboration with Lucence (搜索) strengthens our ability to provide world-class cancer (搜索) diagnostics, offering oncologists and patients access to precision-driven solutions."
Addressing India's Cancer Burden
The partnership comes at a critical time for India's healthcare landscape. With a population of 1.43 billion, the country faces significant challenges in cancer (搜索) care, recording approximately 1.46 million new cancer cases and 916,000 cancer-related deaths annually. The integration of advanced molecular testing technologies aims to enhance diagnostic accuracy and treatment effectiveness for this substantial patient population.
Clinical Applications and Benefits
The implementation of liquid biopsy testing offers several advantages over traditional tissue biopsies, including:
- Non-invasive sampling through blood draws
- Ability to monitor treatment response in real-time
- Detection of molecular changes that might inform treatment adjustments
- Comprehensive molecular profiling for precision medicine approaches
This technological advancement represents a significant step forward in bringing state-of-the-art cancer (搜索) diagnostics to Indian patients, potentially improving treatment outcomes through more precise and personalized therapeutic strategies.